Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Catalyst Biosciences Inc (CBIO) USD0.001

Sell:$4.80 Buy:$5.23 Change: $0.03 (0.61%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.03 (0.61%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.03 (0.61%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

Contact details

611 Gateway Blvd Ste 710
United States
+1 (650) 8710761

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$162.47 million
Shares in issue:
31.37 million
United States
US dollar

Key personnel

  • Nassim Usman
    President, Chief Executive Officer, Director
  • Clinton Musil
    Chief Financial Officer
  • Tom Knudsen
    Senior Vice President - Corporate Development
  • Grant Blouse
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.